{
    "clinical_study": {
        "@rank": "31718", 
        "arm_group": [
            {
                "arm_group_label": "Rapamycin", 
                "arm_group_type": "Experimental", 
                "description": "Rapamycin 3mg orally daily x 4weeks prior to radical cystectomy"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention"
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to evaluate the effects of rapamycin directly on bladder tumors and the\n      effects of rapamycin on the immune system of patients with bladder cancer."
        }, 
        "brief_title": "Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Invasive Bladder Cancer Stage II", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a presurgical clinical trial which aims to understand the biologic activity of TORC1\n      inhibition and safety in patients with bladder cancer.  In this presurgical setting, paired\n      PMBCs and tumor tissue is evaluated before and after exposure to rapamycin to address target\n      specificity, drug delivery, physiologic effects on tumor growth and apoptosis, and\n      correlation of biomarkers with clinical activity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Have invasive (\u2265T1) bladder cancer\n\n          2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n          3. In their treating physician's opinion is a good candidate for radical cystectomy\n\n          4. In their treating physician's opinion does not need neoadjuvant chemotherapy prior to\n             cystectomy\n\n          5. Be able to give informed consent\n\n          6. Be age 18 or older\n\n          7. Have adequate marrow function (defined as granulocytes greater than 1,500 cells/mm3\n             hemoglobin >9.5 gm/dl or platelets more than 100,000 cells/mm3).\n\n          8. Have adequate end-organ function (GFR >30, bilirubin <1.5, SGOT < 3x ULN)\n\n          9. Have a life expectancy > one year\n\n         10. Not have a prior history of non-bladder cancer unless the cancer is clinically stable\n             and not requiring active treatment\n\n         11. Not have received chemotherapy or radiotherapy in the prior 30 days\n\n        Exclusion Criteria:\n\n          1. Immunosuppressed state (e.g. HIV, use of chronic steroids)\n\n          2. Fixed disease (clinical T4)\n\n          3. Active, uncontrolled infections\n\n          4. Hepatic impairment (SGOT >3x ULN)\n\n          5. Unhealed wounds\n\n          6. Patients at risk of pregnancy who are unwilling or unable to take effective\n             contraception before rapamycin therapy, during therapy, and for 12 weeks after\n             discontinuation of therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01827618", 
            "org_study_id": "HSC20120135H", 
            "secondary_id": "KL2 TR000118-05/CTSA"
        }, 
        "intervention": {
            "arm_group_label": "Rapamycin", 
            "intervention_name": "Rapamycin", 
            "intervention_type": "Drug", 
            "other_name": "Sirolimus, Rapamune"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Sirolimus", 
                "Everolimus"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "bladder", 
            "Cancer", 
            "Cystectomy", 
            "Rapamycin"
        ], 
        "lastchanged_date": "December 10, 2013", 
        "location": {
            "contact": {
                "email": "zarateI@uthscsa.edu", 
                "last_name": "Izelda Zarate", 
                "phone": "210-567-5676"
            }, 
            "contact_backup": {
                "email": "garciaee@uthscsa.edu", 
                "last_name": "Eva Garcia", 
                "phone": "210-567-1590"
            }, 
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78229"
                }, 
                "name": "UT Health Science Center San Antonio"
            }, 
            "investigator": {
                "last_name": "Tyler J Curiel, MD, MPH", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Immunopharmacodynamic Phase 0/I Study of Rapamycin in Patients Undergoing Radical Cystectomy for Bladder Cancer", 
        "overall_contact": {
            "last_name": "Izelda Zarate", 
            "phone": "210-567-5676"
        }, 
        "overall_contact_backup": {
            "last_name": "Robert Svatek, MD, MSCI", 
            "phone": "210-567-5676"
        }, 
        "overall_official": {
            "affiliation": "UT Health Science Center San Antonio", 
            "last_name": "Robert S Svatek, MD,MSCI", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "PD response defined by significant phospho rpS6 Kinase 1 (S6K1) inhibition (comparing post-treatment to baseline).", 
            "measure": "Tissue pharmacodynamic (PD) response to TORC1 inhibition", 
            "safety_issue": "No", 
            "time_frame": "30 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01827618"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The University of Texas Health Science Center at San Antonio", 
            "investigator_full_name": "Robert Svatek", 
            "investigator_title": "Assistant Professor, Division of Urologic Oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "The University of Texas Health Science Center at San Antonio", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The University of Texas Health Science Center at San Antonio", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}